Ceregene Inc., of San Diego, reported gene transfer can provide targeted expression of a neurotrophic factor such as neurturin to restore and preserve dying neurons. The research has significance for Parkinson's disease. Ceregene's neurotrophic therapy, CERE-120, is in clinical trials for advanced Parkinson's disease. The results were published in the current issue of Movement Disorders.